Nucleic Acid News and Research

RSS

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc., today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

5 Jan 2011

Prions responsible for BSE can survive in new host environment

Scientists from the Florida campus of The Scripps Research Institute have shown that prions, bits of infectious protein that can cause fatal neurodegenerative disease such as bovine spongiform encephalopathy or "mad cow disease," have the ability to adapt to survive in a new host environment.

17 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

COPAN announces US patent for evoluton in flocked swab technology

COPAN has enjoyed widespread use of its flocked swabs line, branded as FLOQSwabs, in microbiology for the collection and transportation of bacterial and viral samples.

17 Dec 2010

Scientists discover potential strategy for pancreatic cancer therapy

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

15 Dec 2010

Scientists to develop ultra-rapid sexually transmitted infection detection system for clinics

Scientists from the University of Southampton have secured funding to develop an ultra-rapid sexually transmitted infection (STI) detection system for clinics that can detect STIs in under 15 minutes.

9 Dec 2010

Rapid TB test endorsed by WHO

The World Health Organization (WHO) said that a new test that can detect tuberculosis (TB), including drug-resistant forms, in less than two hours could revolutionize treatment of the disease. Tuberculosis is still a major killer worldwide killing 4,700 people every day last year. The annual death toll of 1.7 million includes 380,000 people who are at particular risk because they have HIV, the virus that depresses the immune system and causes Aids.

8 Dec 2010

WHO endorses new rapid fully automated nucleic acid amplification test for TB

Today, WHO endorsed a new and novel rapid test for tuberculosis (TB), especially relevant in countries most affected by the disease. The test could revolutionize TB care and control by providing an accurate diagnosis for many patients in about 100 minutes, compared to current tests that can take up to three months to have results.

8 Dec 2010

IRIS announces product acquisition from BioMicro Systems

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that it has acquired the assets of a multi-purpose, bench-top instrument platform for automating highly repetitive, manual laboratory protocols for (F)ISH (fluorescence in-situ hybridization) testing and other slide-based cytogenetic applications.

30 Nov 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. "These molecules can interact with the estrogen hormone and, thus, even lead to cancer," explains Dr. Joerg Hoheisel; molecular biologist at DKFZ. "The connection between the levels of the estrogen receptor alpha and the occurrence of breast cancer has been known for some time now.

24 Nov 2010

USPTO, EPO issue key patents for Tekmira's LNP technology

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).

23 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

PubDNA Finder search engine links biomedical articles to nucleic acid sequences

Researchers from the Universidad Politécnica de Madrid's Biomedical Informatics Group based at the Facultad de Informática have created a tool called PubDNA Finder. This tool is the first search engine specialized in linking biomedical articles to nucleic acid sequences.

16 Nov 2010

GenturaDx to showcase IDbox molecular diagnostic system at AMP 2010

GenturaDx will display its proprietary molecular diagnostic system, the IDbox System, at the annual meeting of the Association for Molecular Pathology (AMP) in San Jose, Calif. on November 17 – 20, 2010. The IDbox System incorporates all aspects of its proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette.

15 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

New Ovation systems improve nucleic acid extraction from FFPE tissue samples

NuGEN Technologies, the provider of innovative RNA and DNA sample preparation solutions for genomic analysis, today announced the availability of the Ovation WGA FFPE System and the Ovation RNA-Seq FFPE System. These are the first commercially available products designed specifically to enable researchers to utilize next-generation sequencing (NGS) technologies to analyze nucleic acids extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

3 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Nucleic Acid News and Research

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Prions responsible for BSE can survive in new host environment

Study: Biomarkers may aid in early diagnosis of breast cancer

COPAN announces US patent for evoluton in flocked swab technology

Scientists discover potential strategy for pancreatic cancer therapy

Scientists to develop ultra-rapid sexually transmitted infection detection system for clinics

Rapid TB test endorsed by WHO

WHO endorses new rapid fully automated nucleic acid amplification test for TB

IRIS announces product acquisition from BioMicro Systems

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

USPTO, EPO issue key patents for Tekmira's LNP technology

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

PubDNA Finder search engine links biomedical articles to nucleic acid sequences

GenturaDx to showcase IDbox molecular diagnostic system at AMP 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

New Ovation systems improve nucleic acid extraction from FFPE tissue samples

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery